Early Bactericidal Activity of Different Isoniazid Doses for Drug Resistant TB (INHindsight): A Randomized Open-label Clinical Trial

Kelly E. Dooley,Sachiko Miyahara,Florian von Groote-Bidlingmaier,Xin Sun,Richard Hafner,Susan L. Rosenkranz,Elisa H. Ignatius,Eric Nuermberger,Laura Moran,Kathleen Donahue,Susan Swindells,Naadira Vanker,Andreas H. Diacon

Early Bactericidal Activity of Different Isoniazid Doses for Drug Resistant TB (INHindsight): A Randomized Open-label Clinical Trial

2020

Kelly E. Dooley
Sachiko Miyahara
Florian von Groote-Bidlingmaier
Xin Sun
Richard Hafner
Susan L. Rosenkranz
Elisa H. Ignatius
Eric Nuermberger
Laura Moran
Kathleen Donahue
Susan Swindells
Naadira Vanker
Andreas H. Diacon

Rationale: High-dose isoniazid is recommended in short-course regimens for multidrug-resistant TB (MDR-TB). The optimal dose of isoniazid and its individual contribution to efficacy against TB stra...

Keywords:

Drug resistance
Anesthesia
Internal medicine
Clinical trial
Diabetes mellitus
Medicine
Isoniazid
open label
Tuberculosis
INHA
Phases of clinical research
drug resistant tuberculosis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations